Edwards Lifesciences Corporation stock research
FY2026 Q1
Edwards Lifesciences (EW) Gross Margin & Quarterly History
Explore Edwards Lifesciences Corporation (EW) gross margin from 2023 through the latest reported quarter, using SEC-sourced revenue, gross profit, and direct costs.
Gross margin takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue and gross profit both increased year over year, while cost of revenue rose at a faster pace, causing a slight decline in gross margin. Sequentially, revenue was stable but gross margin edged lower as cost growth outpaced revenue.
- The primary driver was higher gross profit supported by increased revenue, though the margin tightened as cost of revenue rose. The net effect was a modest weakening in profitability efficiency.
- Compared to the prior quarter, gross margin was slightly lower, and versus the same quarter last year, gross margin decreased. Revenue was higher year over year but flat sequentially.
Gross margin snapshot
The selected quarter's reported revenue, gross profit, direct costs, and margin comparisons.
Gross margin
78.0%
Gross profit
$1.3B
Revenue
$1.6B
Cost of revenue
$362.6M
Quarter-over-quarter change
-0.1 pts
Year-over-year change
-0.6 pts
Quarterly gross margin trend
A four-quarter view of the revenue and direct-cost bridge behind gross margin.
| Period | Revenue | Gross profit | Cost of revenue | Gross margin |
|---|---|---|---|---|
| Jun 30, 2025 | $1.5B | $1.2B | $344.4M | 77.5% |
| Sep 30, 2025 | $1.6B | $1.2B | $345.2M | 77.8% |
| Dec 31, 2025 | $1.6B | $1.2B | $343.0M | 78.1% |
| Mar 31, 2026 | $1.6B | $1.3B | $362.6M | 78.0% |
Quarterly comparisons
Compare the selected margin with the preceding quarter and the same fiscal quarter one year earlier.
Previous-quarter change
Dec 31, 2025
-0.1 pts
Year-over-year change
Mar 31, 2025
-0.6 pts
What the margin says
Filing-constrained interpretation of margin direction, comparisons, and what to monitor next.
The primary driver was higher gross profit supported by increased revenue, though the margin tightened as cost of revenue rose. The net effect was a modest weakening in profitability efficiency.
Compared to the prior quarter, gross margin was slightly lower, and versus the same quarter last year, gross margin decreased. Revenue was higher year over year but flat sequentially.
Monitor the trajectory of cost of revenue relative to revenue, as its faster growth has been compressing margins.
Peer context
Latest available gross margins for related public companies.
| Company | Gross margin |
|---|---|
| Edwards Lifesciences Corporation (EW) | 78.0% |